Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of June 2019. The report documents the outcomes of the Company's 2019 Annual General Meeting of Shareholders held on June 26, 2019, in Rehovot, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report regarding shareholder meeting resolutions and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The document focuses on the approval of corporate governance proposals, including board re-elections and executive compensation plans.
Guidance, Outlook, and Management Commentary
- Board Re-election: Shareholders approved the re-election of the entire current Board of Directors for a one-year term. Directors include Martin S. Gerstel, Sarit Firon, Ziv Kop, Adrian Percy, Leon Y. Recanati, and Oded Shoseyov.
- Executive Compensation: The meeting approved initial and subsequent annual option grants for directors Dr. Adrian Percy and Dr. Oded Shoseyov. Additionally, shareholders approved the objectives and potential 2020 cash bonus for President & CEO Ofer Haviv, contingent on 2019 performance targets.
- Auditor Ratification: Kost Forer Gabbay & Kasierer (a member firm of Ernst & Young Global) was re-appointed as the independent registered public accounting firm for the year ending December 31, 2019.
Investor Verification Checklist
- Verify the specific performance objectives for CEO Ofer Haviv's 2019 bonus plan in the referenced proxy statement (Exhibit 99.2).
- Confirm the details of the option grants approved for directors Dr. Percy and Dr. Shoseyov.
- Review the Company's most recent Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.